BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida. Interested investors and guests o ...

Core Insights - Sunshine Biopharma Inc. has developed a new series of orally active, non-covalent protease inhibitors with dose-dependent antiviral activity against SARS Coronavirus (SARS-CoV-2) [1] - The research was conducted in collaboration with the University of Arizona [1] Company Developments - The new protease inhibitors are aimed at providing life-saving medicines in therapeutic areas including oncology and antivirals [1] - The ongoing collaboration with the University of Arizona highlights the company's commitment to advancing its research capabilities [1]